As of 12:31 PM on the 18th, Seegene is trading at 264,400 KRW, down 1.78% from the previous day. The trading volume is 472,394 shares, which is about 38.58% of the previous day's volume. Seegene is known as a company that develops, manufactures, and sells molecular diagnostic reagents.
On September 16, Hana Financial Investment researchers Minjeong Seon and Seungwon Kang stated, "With third-quarter sales increasing compared to the second quarter, Seegene's sales this year are estimated to exceed 1 trillion KRW. Due to the high transmissibility of the COVID-19 virus, which can cause outbreaks as soon as quarantine measures are relaxed, the pandemic is expected to become a long-term battle. In 2021, Seegene's sales are also expected to increase by more than 7%, maintaining sales around 1.1 trillion KRW. Given the long-term nature of the COVID-19 pandemic and earnings growth in the third and fourth quarters, there is a need to re-rate the valuation." They set Seegene's target price at 350,000 KRW.
Over the past five days, individual investors have net sold 61,528 shares of Seegene, while foreign investors and institutions have net bought 50,722 shares and 56,747 shares, respectively.
※Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
